Group 1 - The company held its 14th meeting of the 8th Board of Directors on November 10, 2025, to address urgent matters, waiving the notice period as per company regulations [2][5] - All six directors attended the meeting, which was chaired by the Chairwoman, Ms. Dou Qiling [3][4] - The meeting was compliant with the Company Law and the company's articles of association [5] Group 2 - The Board approved the proposal to supplement an independent director, with Ms. Liang Liang nominated as a candidate to replace Mr. Chen Yisong, who resigned for personal reasons [6][12] - Mr. Chen's resignation will only take effect after a new independent director is elected at the shareholders' meeting to ensure compliance with legal requirements [12][13] - The proposal for the election of the new independent director will be submitted for approval at the company's second extraordinary general meeting scheduled for November 26, 2025 [8][21] Group 3 - The company will hold its second extraordinary general meeting on November 26, 2025, at 10:00 AM, combining on-site and online voting methods [21][22] - The meeting will discuss the proposal to supplement the independent director, contingent upon approval from the Shanghai Stock Exchange [21][23] - Shareholders can vote through the Shanghai Stock Exchange's online voting system during specified time frames on the day of the meeting [22][24] Group 4 - Ms. Liang Liang, the independent director candidate, holds a Ph.D. in management and is currently an associate professor at Guizhou University, with no prior shareholding in the company [11][16] - The company confirmed that Ms. Liang meets all qualifications to serve as an independent director and has no conflicts of interest with major shareholders or other board members [14][19] Group 5 - The company also announced the election of Mr. Jiang Tao as the employee representative director during the first employee representative assembly held on November 10, 2025 [17][18] - Mr. Jiang holds a master's degree in software engineering and has served in various roles within the company [18][19]
贵州益佰制药股份有限公司 第八届董事会第十四次会议决议公告